{
    "nct_id": "NCT05640245",
    "official_title": "Phase 2, Randomized, Parallel-group, Double-blind, Placebo-controlled Study of Sonelokimab in Patients With Active Psoriatic Arthritis",
    "inclusion_criteria": "1. Participant is ≥18 years of age;\n2. Participant has a confirmed diagnosis of PsA per the 2006 Classification criteria for Psoriatic Arthritis (CASPAR) with symptoms for ≥6 months prior to the Screening Visit;\n3. Participant has active disease (defined by a TJC68 of ≥3 and a SJC66 of ≥3);\n4. Participant has either current active PsO or a dermatologist confirmed history of PsO;\n5. Participant tests negative for rheumatoid factor (RF) at the Screening Visit;\n6. Participant tests negative for anti-cyclic citrullinated peptide (CCP) antibodies at the Screening Visit;\n7. Participant must be, in the opinion of the investigator, a suitable candidate for treatment with adalimumab per approved local product information.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Participant with known hypersensitivity to sonelokimab or any of its excipients;\n2. Participant with known hypersensitivity to adalimumab or any of its excipients;\n3. Participant who has previously failed on anti-interleukin (IL)-17 therapy;\n4. Participant who has previously failed on anti-tumor necrosis factor alpha (TNFα) therapy;\n5. Participant who has had previous exposure to more than 2 biologic agents of any type to treat PsA prior to the Screening Visit;\n6. Participant who has a diagnosis of chronic inflammatory conditions other than PsO or PsA;\n7. Participant who has a diagnosis of arthritis mutilans",
    "miscellaneous_criteria": ""
}